Sign Up NowThis Month's Tiny Gems - October 2012

Brightcove, Inc. (BCOV)
Cardium Therapeutics, Inc. (CXM)
GreeneStone Healthcare Corp. (GRST)

 

 

 

Brightcove, Inc. (BCOV)

 

Brightcove, Inc. (BCOV) is well-positioned as a recognized online video platform provider, with customers using the flash-based on-demand Video Cloud service to deliver some 743M video streams per month in 2011. The BCOV solution set is perfect for high-end usage among professional media enterprises and encompasses full lifecycle coverage for the video, from upload/encode through to templates, automatic variety of streaming types, analytics, and easy integration with different advertising technologies/platforms.

 

Support for multiple devices, secure management, scheduling, and dense analytics have made BCOV a very attractive choice for media professionals and enterprises looking to have total control over the content. New offerings, like the Brightcove App Cloud, create a huge opportunity for open standard-developed apps for iOS or Android smartphones/tablets using HTML5, providing the cloud infrastructure needed to connect to powerful content services.

 

A powerful feature set really sets BCOV apart, with everything from extensions and integrations to advertising and monetization tools. The platform has been embraced by the likes of Showtime®, which recently joined with Brightcove and popular streaming player provider Roku to deliver sample clips and other content directly to Roku devices via the Brightcove Video Cloud as part of a new interactive application rolled out for their hit series Shameless and a new comedy series.

 

Founder, Chairman and CEO of BCOV, Jeremy Allaire, is widely known for his work developing ColdFusion, which was acquired by Macromedia back in 2001 (now part of Adobe). The company has a serious cloud-based video ecosystem model for professionals and while investors may be talking a lot about entry of larger players like Apple and Google, it is largely because they do not understand the sophisticated execution BCOV has implemented, nor its passion for continued innovation and the genuine enthusiasm of an established user-base.

 

 

 

Cardium Therapeutics, Inc. (CXM)

 

Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.

 

The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.

 

Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.

 

Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value.

 

 

 

GreeneStone Healthcare Corp. (GRST)

 

GreeneStone Healthcare Corp. (GRST) is focused on operating medical and healthcare clinics in Ontario, Canada, offering addiction treatment, colonoscopy, endoscopy, minor cosmetic procedures, and executive health assessment programs. The company adds overflow capacity to an increasingly stretched provincial healthcare system, and provides private alternatives to publicly underserviced healthcare needs.

 

Ontario's public healthcare cost has grown at a compounded 7.1% rate over the past 10 years, now accounting for approximately $77B in government spending compared to $39B in 2000. This cost explosion is similar for the country as a whole, growing at 7.4% over the same period. The need for practical change to the system is immediate as demand continues to rise.

 

Governments are increasingly looking to private alternatives to address the growing trade-off between costs vs. service in the public healthcare system. Private services are expanding beyond their traditional place as overflow capacity to relieve wait times. GreeneStone Healthcare is particularly well positioned with a first-mover advantage in mental healthcare – a highly underserviced niche.

 

The company currently offers its various medical services via three medical clinics. Future plans include establishing partnerships for accelerated growth as well as dual-listing on CNSX. With positive revenue growth and cash flow positive status recently achieved, GreeneStone is methodically extending its vertical expertise in the healthcare industry.